385 Oyster Point #9A
South San Francisco
121 articles with Vaxart, Inc.
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Vaxart oral tablet vaccine provided 39% reduction in flu illness compared to 27% for Fluzone®
Vaxart ended the quarter with cash and cash equivalents of $23.9 million compared to $17.5 million at March 31, 2018.
Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
Vaxart, Inc. today announced publication of the comprehensive results of the previously disclosed Phase 1 clinical trial with its norovirus oral tablet vaccine in the Journal of Clinical Investigation Insight.
Vaxart, Inc. reported the topline results from a Phase 2 clinical trial evaluating the safety and efficacy of an antiviral teslexivir 5% gel.
Vaxart, Inc. announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the Jefferies 2018 Global Healthcare Conference.
Vaxart, Inc. announced that Roberto Mateo, Ph.D., lead scientist of Vaxart, will present data on the Phase 1 norovirus vaccine trial in a poster presentation at the American Society of Microbiology 2018.
Vaxart, is a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection
2017 Net Sales of Inavir® in Japan Exceeded ¥20 Billion, Triggering USD $5 Million Milestone Payment
Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President, Commercial Operations.
Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress
Vaxart, Inc. announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine will be highlighted in an oral presentation at the World Vaccine Congress (WVC), taking place from April 2-5, 2018 in Washington, D.C.
Issued Claims Cover High Yield Production Process of Phase 2 Antiviral
In connection with the merger, Aviragen Therapeutics, Inc. changed its name to Vaxart, Inc. and effected a 1-for-11 reverse split of its common stock.
Vaxart announced today it has reached an understanding with the CAS Group under which East Hill, a major shareholder in Aviragen, will support the merger between Vaxart and Aviragen.
The Company previously announced that the special meeting of Aviragen stockholders, originally scheduled for February 6, 2018.
Under the new terms, Aviragen stockholders would now own 49% of the combined company, up from 40% under the previous agreement.
The following is a statement from Wouter Latour, M.D., Chief Executive Officer of Vaxart, who will lead the combined company following completion of the transaction:
Vaxart Announces Its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase II Challenge Study
Vaxart announced today that its investigational H1 influenza oral tablet vaccine demonstrated a statistically significant reduction in the rate of influenza infection compared with placebo, and compared favorably with the market-leading injectable quadrivalent influenza vaccine (QIV) in a Phase 2 challenge trial.
ISS Recommends Aviragen Stockholders Vote AGAINST the Vaxart Merger on the CAS Group's BLUE Proxy Card
In reaching its conclusion, ISS performed a detailed review of both sides' positions in the election contest as well as its own thorough independent analysis.
Vaxart Announces Positive Safety and Immunogenicity Results for Its Oral Norovirus Vaccine in A Phase 1b Clinical Study
The norovirus tablet vaccine was generally well tolerated in all subjects. Adverse events (AEs) were mostly mild in severity with headache as the most frequent AE.